文献速递神经肿瘤

超越大本营:PI3K/mTOR抑制治疗儿童高级别胶质瘤

Beyond base camp: PI3K/mTOR inhibition for the treatment of pediatric high-grade gliomas.
PubMed 文献 · Neuro Oncol · 2025-01-01

儿童高级别胶质瘤(pHGG)包括弥漫性中线胶质瘤(DMG)是最具侵袭性和致死性的儿童癌症。PI3K通路突变驱动肿瘤生长、治疗抵抗和不良预后,但血脑屏障限制大多数PI3K/mTOR抑制剂的递送,且适应性耐药机制削弱疗效。本文综述靶向PI3K/mTOR通路的希望与陷阱,包括现有治疗局限、耐药机制及改进方案设计的迫切需求,并提出未来路线图。

要点

  • PI3K通路突变和扩增是pHGG生长、耐药和不良预后的驱动因素。
  • 血脑屏障限制大多数PI3K/mTOR抑制剂的中枢神经系统渗透。
  • 新型脑渗透性PI3K/mTOR抑制剂带来新机会,但联合治疗需平衡毒性与疗效。

核心结论

  • 靶向PI3K/mTOR通路在DMG治疗中具有前景但面临多重挑战,需合理联合策略和更好的患者分层以改善生存。

研究设计与样本

  • 综述,探讨靶向PI3K/mTOR通路在DMG治疗中的前景与局限。

主要发现

  • PI3K/mTOR抑制剂因血脑屏障限制而中枢神经系统渗透差。
  • 即使进入脑内,这些药物常遇到适应性耐药机制而削弱疗效。
  • 不良反应包括高血糖、皮疹和黏膜炎,进一步复杂化使用并降低依从性。

临床怎么用

  • 新型脑渗透性PI3K/mTOR抑制剂可与化疗、其他小分子和免疫治疗联合,但需仔细平衡毒性与疗效。
  • 实现每个患者的最佳剂量仍是重大障碍。

局限性

  • 综述未报告原始研究的具体样本量、阈值或统计数值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pediatric high-grade glioma (pHGG), including diffuse midline glioma (DMG), are the most aggressive and fatal pediatric cancers. Mutations and amplifications within the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway drive tumor growth, treatment resistance, and poor outcomes. Although PI3K and mTOR have been identified as genetic dependencies in pHGGs, translating this knowledge into effective treatment remains challenging. The blood-brain barrier (BBB) restricts the delivery of most PI3K/mTOR inhibitors and , hence, often show poor CNS penetration. Even when present in the brain, these agents frequently encounter adaptive resistance mechanisms that blunt efficacy. Side effects, including hyperglycemia, rash, and mucositis, further complicate their use and reduce compliance. Encouragingly, novel brain-penetrant PI3K/mTOR inhibitors offer new opportunities for treatment, but combining these agents with other therapies, including chemotherapy, other small molecules, and immunotherapies, requires careful balancing of toxicity and efficacy. Therefore, achieving optimal dosing for each patient remains a significant hurdle. This review examines the promise and pitfalls of targeting the PI3K/mTOR pathway in DMG, including the limitations of available therapies, mechanisms of resistance, and the critical need for improved regimen design. We propose a roadmap to guide future efforts, emphasizing rational combination strategies and better patient stratification to improve survival for children diagnosed with these devastating cancers.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Duchatel RJ, Savary C, Germon ZP, et al. Beyond base camp: PI3K/mTOR inhibition for the treatment of pediatric high-grade gliomas. Neuro Oncol. 2025. PMID: 41626633. doi:10.1093/neuonc/noaf163

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。